SUPPORT FOR "EMERGING TECHNOLOGY":  STUDIES ON THE AUGMENTATION OF CELLULAR
  AND HUMORAL IMMUNE FUNCTION TO INCREASE THE PROTECTIVE IMMUNE RESPONSE TO HIV
  INFECTION
     
MASTER AGREEMENT ANNOUNCEMENT AVAILABLE:  NCI-CP-95666-45
     
P.T. 34; K.W. 0745045, 0715008, 0760080, 0740023
     
National Cancer Institute
     
The National Cancer Institute, Division of Cancer Etiology is soliciting
proposals from offerors with the capability to conduct Studies on the
Augmentation of Cellular and Humoral Immune Function to Increase the
Protective Immune Response to HIV Infection.  The successful offeror must be
able to develop procedures for immune therapy in HIV-infected human subjects
with purified HIV proteins and/or recombinant vector expressing HIV proteins.
     
The offeror must obtain consent and human subject protection certification;
furnish information on protocols used and results obtained; and provide
samples or serum and/or cells from the immunized subjects to NCI upon request.
     
It is anticipated that a Master Agreement Award will be made FOR A PERIOD OF
FORTY-EIGHT (48) MONTHS.  MASTER AGREEMENTS CONSIST OF A POOL OF PREQUALIFIED
OFFERORS.  After award, groups of Master Agreement holders will be invited to
propose competitively on Master Agreement Orders that will be designed to
accomplish a specific task to be designated by the Government.
     
Master Agreement announcement No. NCI-CP-95666-45 for the task described above
will be available to interested offerors on approximately October 21, 1989.
Responses will be due approximately 30 days after the publication date of this
announcement.  Copies of this RFP may be obtained by sending a written request
to:
     
Opal J. Bailey
Contract Specialist
Cancer Etiology Contract Section, Research Contracts Branch
National Cancer Institute
Executive Plaza South, Room 620
Bethesda, Maryland  20892
     
                  Vol. 18, No. 38, October 27, 1989 - Page 2
                                   NIH GUIDE